Regen BioPharma (Regen BioPharma) 3-Year Revenue Growth Rate : -17.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Regen BioPharma 3-Year Revenue Growth Rate?

Regen BioPharma's Revenue per Share for the three months ended in Mar. 2024 was $0.00.

During the past 12 months, Regen BioPharma's average Revenue per Share Growth Rate was -32.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -17.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -32.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Regen BioPharma was -2.10% per year. The lowest was -59.20% per year. And the median was -43.15% per year.

Competitive Comparison of Regen BioPharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Regen BioPharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's 3-Year Revenue Growth Rate falls into.

Regen BioPharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Regen BioPharma (OTCPK:RGBPP.PFD) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Regen BioPharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma (Regen BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBPP.PFD) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

RGBP:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.